The National Academy of Medicine is bringing together science, technology, and policy professionals from the Washington, D.C., region for breakfast and conversation as we explore how breakthroughs in synthetic cell systems could transform biomedical and health applications, including therapeutics, diagnostics, regenerative medicine, and distributed biomanufacturing.
Synthetic cells are emerging as a platform for biomedical innovation as advances in engineering biology make it increasingly possible to design programmable cellular systems with lifelike functions. Recognizing both the promise and potential risks of this rapidly advancing field, the National Academies recently examined environmental, biosafety, and biosecurity considerations associated with synthetic cell research and development, highlighting priorities for responsible innovation and risk governance.
Agenda:
- Breakfast & Networking
- Presentation by Richard M. Murray, Thomas E. and Doris Everhart Professor of Control & Dynamical Systems and Bioengineering at the California Institute of Technology
- Reflection on Responsible Innovation and Governance for Synthetic Cell Therapies by Peter Marks, Senior Vice President of Molecule Discovery and Head of Infectious Disease, Eli Lilly
- Discussion moderated by Alta Charo, Warren P. Knowles Professor of Law and Bioethics emeritus at the University of Wisconsin–Madison
- Informal Discussion and Networking
Bagels and Biotech is an initiative of the NAM Action Collaborative on Translating Emerging Science, Technology, and Innovation in collaboration with the National Academies Programs on Biomedical and Health Sciences & Life Sciences and Biotechnology.
